{"id":"W2793957208","doi":"10.1200/jco.2018.36.6_suppl.3","title":"PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Placebo; Hazard ratio; Gynecology; Randomized controlled trial; Urology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003243032,0.0019628,0.003254678,0.0005544106,0.0006626031,0.001139907,0.001155273,0.0023616,0.009109117],"category_scores_gemma":[0.002559427,0.000746974,0.002266495,0.0004999128,0.00108862,0.001173531,0.000543925,0.00264867,0.001392226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000640792,"about_ca_system_score_gemma":0.002406287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001365497,"about_ca_topic_score_gemma":0.004717207,"domain_scores_codex":[0.9989532,0.0007045945,0.00005760599,0.0001196422,0.00007302978,0.00009184357],"domain_scores_gemma":[0.9991283,0.0002627737,0.0002442208,0.00006023361,0.00007933251,0.0002252051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9659792,0.003491758,0.0005235966,0.004628614,0.001393753,0.00006690247,0.00008811182,0.0002725351,0.003246752,0.000315573,0.002795242,0.01719796],"study_design_scores_gemma":[0.9826186,0.01427877,0.0007843177,0.00009786605,0.000368478,0.00003435884,0.00001308266,0.00009490227,0.0002011485,0.0001241535,0.001374822,0.000009560878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8543278,0.06440668,0.004494895,0.003244552,0.002745647,0.04348605,0.01322285,0.001023527,0.01304803],"genre_scores_gemma":[0.8810115,0.03082583,0.01225003,0.005327591,0.001166049,0.04822945,0.00687899,0.0001599411,0.0141506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009109117,"threshold_uncertainty_score":0.03047299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1390578545749188,"score_gpt":0.5135764442932255,"score_spread":0.3745185897183067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}